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Abstract
Background: With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been
unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two
treatments modalities is unknown. Combining or sequencing these agents could potentially result in unique
toxicities. Cutaneous adverse events (CAE) after sequential exposure to these agents represents one toxicity that
needs further description.
Methods: After retrospectively reviewing charts of patients from 2015 to 2018, we identified six patients who
experienced CAEs after recent exposure to sequential immunotherapy and TT or vice versa for the treatment for
metastatic melanoma at the University of North Carolina, Chapel Hill. Skin biopsies were available in five patients.
Results: Five patients received TT after immunotherapy, and one patient received immunotherapy after TT. TT
consisted of vemurafenib/cobimetinib (V/C) in five patients with four patients starting V/C immediately before
manifesting with a CAE. In patients receiving V/C after immunotherapy, the median time from beginning V/C to
development of CAE was 14.5 days. The clinical presentation of diffuse morbilliform rash, fevers, hypotension, and
end-organ damage raised concern for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome.
Histopathological features of lympho-eosinophilic infiltrate were supportive of a drug eruption. Immunotherapy or
TT were re-initiated in five patients within 1–8 weeks after resolution of the index CAE. This resulted in two patients
re-experiencing the CAE. Both of these patients were off prednisone at the time of therapy re-initiation, whereas
none of the patients who were restarted on targeted therapy with a steroid overlap had a rash recurrence.
Conclusions: Sequential treatment using immunotherapy and TT, especially the sequence of V/C after immunotherapy
appears to be the most common trigger for CAE with a median time to onset of approximately 2 weeks. Although the
clinical presentation of these CAEs can be dramatic, they respond well to prednisone therapy. This unique presentation
suggests that it may be reasonably safe to re-challenge certain patients with a steroid overlap after rash resolution.
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Introduction
With the advent of immune-checkpoint inhibitors and
novel targeted therapies (TT), the treatment landscape
for melanoma has witnessed a paradigm shift with un-
precedented survival and response rates both in the ad-
juvant and the metastatic settings [1]. This, in turn, has
prompted a revolution that has gradually spread across
certain other tumor types, resulting in remarkably im-
proved outcomes. Around 40–50% of cutaneous melano-
mas harbor mutations in the B-RAF gene with V600E
accounting for 80–90% in this category. One of the
standard approaches for B-RAF V600E mutated melano-
mas involves using B-RAF inhibitors in conjunction with
MEK inhibitors [2]. Immune-checkpoint blockade (ICB)
involving the use of monoclonal antibodies to modulate
the immune checkpoints such as programmed cell
death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4
(CTLA-4) is the other rapidly evolving approach that
has demonstrated strong potency and durable efficacy in
the frontline treatment of advanced melanomas includ-
ing B-RAF mutated melanomas [1, 3].
In addition to various clinical factors, determining the
primary and the salvage agent of choice to treat
advanced-stage B-RAF V600E melanomas can be guided
by the differential activities of ICB and TT. For example,
TT have a rapid onset of action while ICB produces sus-
tained responses providing an overall survival “tail” [1,
4]. Also, in response to disease progression, sequencing
ICB and TT in B-RAF mutated melanoma is a reason-
able approach frequently practiced in the real-life set-
ting. The clinical benefit of a sequencing approach is
supported by compelling pre-clinical data demonstrating
the immune modulatory effects of TT that may serve to
augment an endogenous anti-tumor response and thus
achieve synergy with ICB [5, 6]. Presently, however, the
paucity in efficacy and toxicity data from randomized
studies tends to be a barrier in implementing these
sequential or combination strategies into regular clin-
ical practice.
In our case series, we focus on patients treated with ICB
followed by TT, or vice versa, who experienced cutaneous
toxicities with unique histological patterns, a feature that
has not been well described in the literature. We also at-
tempt to understand certain common denominators that
could have contributed to these presentations. Further-
more, we explore possible mechanisms of toxicity and
diagnostic pitfalls that could help guide management in
such scenarios.
Materials and methods
After institutional review board approval, we retro-
spectively reviewed charts from March 2015 to
September 2018 to identify patients experiencing cuta-
neous adverse events (CAE) on receiving sequential
ICB and TT or vice versa for the treatment of meta-
static melanoma at the University of North Carolina,
Chapel Hill. We identified five patients who received
TT after ICB and one patient who received ICB after
TT. Skin biopsies were available in five patients for bet-
ter characterization of the cutaneous reactions. We also
collected relevant data on laboratory parameters, clin-
ical course, and management.
Results
(Table 1) All our patients were of Caucasian ethnicity
with a median age of 58 years when diagnosed with
CAE. Five of the six patients were female. The se-
quence of treatment timeline and CAE are depicted
in Fig. 1. A total of five cases (patients 1–4 and pa-
tient 6) received ICB before TT as the two most re-
cent treatment modalities before experience a CAE.
Only Patient 5 received ICB after TT. In the five pa-
tients who received ICB before TT, the median time
from discontinuation of the most recent ICB to CAE
was 56 days (24–228 days). In four patients (patients
1–4) nivolumab was given for ICB before TT. Pem-
brolizumab was utilized for ICB in two patients, with
patient-5 receiving it after TT and patient-6 receiving
it before TT. ICB was primarily used as a single agent
with the only exception being patient-1 where one
dose of ipilimumab had been given with nivolumab
followed by nivolumab alone. Before switching to TT,
the median number of ICB doses for the five patients
receiving TT after ICB was 12 (1–22 doses). In our
cohort, TT consisted of vemurafenib/cobimetinib (V/
C) in five patients (patients-1 and 3–6) with four pa-
tients (patients 1, 3, 4 and 6) receiving V/C immedi-
ately before manifesting with a CAE. In patients that
specifically received TT in the form of V/C after ICB,
the median time from starting V/C to development of
CAE was 14.5 days (12–21 days). Patient 2 was on
dabrafenib/trametinib (D/T) for a considerable period
(214 days) before developing the CAE. The timeline
for the rash in patient-2 coincided with starting
amoxicillin/clavulanic acid for a pneumonia. Patient-5
developed the CAE immediately after one dose of
pembrolizumab. Patient-3 had been previously treated
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with D/T before switching to ICB but tolerated both
these agents for a considerable time without any tox-
icity. However, when switched from ICB to V/C, he
manifested with the rash immediately within 16 days
from the switch. All four patients who presented with
signs and symptoms consistent with systemic inflam-
matory response syndrome (SIRS) including high-
grade fevers, hypotension, and end-organ damage re-
quired hospitalization (patients 1, 2, 3 and 5). The
values for C-reactive protein were available in three
patients with all values measuring > 150 mg/L (refer-
ence range < 10.0 mg/L). Oral mucositis was an ac-
companying feature in two of the six patients
(patients 1 and 2). Most of the patients had grade-4
CAE based on the Common Terminology Criteria for
Adverse Events (CTCAE 4.03) system (Table 1). The
CAE was mainly characterized by a diffuse erythema-
tous morbilliform eruption involving ≥30% body sur-
face area (Fig. 2) with histopathology primarily
comprising of a lympho-eosinophilic infiltrate (Fig.
3b). Patient 2 was the only exception where sub-epi-
dermal vesicle formation suggestive of bullous pem-
phigoid was seen. As part of a comprehensive
assessment, patient-1 had serum cytokines measured,
and notably, the level for the interleukin-2 receptor
(IL-2R) was seen to be > 20 times the upper limit
(Table 1).
(Table 2) Apart from supportive care, corticosteroids
were an integral part of the management of the CAE.
The dose and duration for steroid use were based on the
severity of the initial presentation. Patients that had
more severe clinical presentations were started on higher
doses with a protracted taper (patient-2, 3 and 5) while
as patients that had relatively milder clinical presenta-
tions and lower intensity rash (for example patient-4 and
6) were started on lower doses which were continued for
a shorter period of time. After stopping the treatment
and initiating supportive care, by week three resolution
in the CAE was observed in a majority (patients 3–6),
while patients-1 and 2 took approximately 6 weeks for
the rash to resolve. ICB or TT was reinitiated in five pa-
tients within 1–8 weeks after resolution of the index
CAE. This resulted in two patients (Patients 3 and 4)
re-experiencing the CAE. Both of these patients were off
prednisone at the time of therapy re-initiation, whereas
none of the patients in our series who were restarted on
TT with a steroid overlap (Patients 1, 2 and 6) had a
rash recurrence. Patient 5 relapsed with a rash on day 54
after the index rash when she was tapered down to 5mg
prednisone. Following this, her dose for prednisone was
increased again with a protracted taper. Patient 2 experi-
enced controlled disease for more than 1 year after reini-
tiating TT without recurrence of adverse events. Patient
6 remains on TT, now greater than 6 months since reini-
tiating it. Despite the initial recurrence of rash in patient
3, he was able to be restarted on TT a second time, with
steroid overlap, and to stay on this for greater than 9
months after that without additional CAEs. Patient 4
was switched to dabrafenib/trametinib (D/T) 166 days
after the index CAE with gradual dose escalation, which
she tolerated well despite rash recurrence when previ-
ously re-challenged with V/C. Subsequently, patient 4
had to be switched from D/T to ipilimumab due to dis-
ease progression and died within 1 month thereafter.
Two of the six patients (patients 1 and 5) were noted to
have disease progression on revaluation after 4–8 weeks
Fig. 1 Therapy timelines for patients in relation to rash onset showing sequencing of ICB and TT
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of the CAE. In the entire cohort of 6 patients, two pa-
tients continue to be alive, receiving ongoing treatment
(patient 6 on D/T and patient 2 on ICB).
Discussion
The biological rationale of combining or sequencing ICB
with TT in metastatic melanoma stems from a growing
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body of evidence supporting the favorable immune effects
created by the oncogene-targeted therapies directed at the
BRAF/MAPK pathway [4]. These beneficial effects that
lead to potentiation of the immune effector function
within the tumor microenvironment are mediated
through various mechanisms, including effects on den-
dritic cell function, natural-killer-cell activation, increased
HLA expression, upregulated expression of melanoma-de-
rived antigens and T-cell homing to the tumor [5–7].
In this case series, we discuss cutaneous toxicity pat-
terns in patients with B-RAF positive metastatic melan-
oma treated with sequential strategies involving ICB and
TT in response to disease progression. Although very re-
cently similar findings have been described by others in
patients receiving TT after ICB [8], we provide a broader
description of the unique histopathological characteris-
tics and also attempt to address questions relating to
management strategies as well as the feasibility of
re-challenging patients with these agents in certain
circumstances.
As shown in Table 1, five of the six patients re-
ceived ICB before TT and tolerated anti-PD-1 therapy
without any overt concerns of toxicity. This raises
speculation of immune priming by ICB followed by
immune boosting by the TT which may result in aber-
rant immunomodulation. Findings from a recently pub-
lished report elucidate worse clinical presentations
associated with cutaneous toxicities to vemurafenib in pa-
tients previously exposed to nivolumab [9], lending proof
of concept to the hypothesis of durable activation of
T-effector cells by prior anti-PD-1 therapy triggering
hypersensitivity to TT. Interestingly, in our series where
patients had prior ICB use, the occurrence the CAE usu-
ally manifested within the first two to 3 weeks from
Fig. 2 Diffuse morbilliform eruption involving trunk (a, b) and extremities (c)
Fig. 3 Skin biopsy of rash with histology. a Skin biopsy shows slight basal layer vacuolization, dermal edema and a superficial dermal perivascular
lymphocyte and eosinophil infiltrate. No necrosis is present. (H&E, 200X). b Eosinophils (arrows) are present with lymphocytes around the superficial
dermal capillaries fibrinoid necrosis of capillary walls, a sign of vasculitis, is not present. (H&E, 400X)
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introduction of vemurafenib-based TT combinations.
These findings are consistent with other reports of adverse
cutaneous responses manifesting within a similar timeline
in patients treated with vemurafenib after exposure to
nivolumab [10, 11] and ipilimumab [12]. Most of these
reported cases used single agent vemurafenib without
concurrent MEK inhibition following ICB. This is in
contrast to our series and a series by another group [8]
where the B-RAF/MEK combination was used, albeit
with similar findings. For now, mechanisms dictating
augmented toxicity with vemurafenib containing com-
binations following ICB remain unclear, which has
prompted us to modify our clinical practice by incorp-
orating dabrafenib instead of vemurafenib for B-RAF
inhibition when choosing TT combinations after dis-
ease progression on ICB.
Most of the patients had clinical features consistent
with SIRS. In a subset of patients, these cutaneous ad-
verse events were associated with a rise in makers of in-
flammation such as C-reactive protein (Table 1). It is
notable to mention that in addition to other pro-inflam-
matory cytokines, one patient also had a high level of
the soluble interleukin-2 receptor (IL-2R), a nonspecific
marker of T-lymphocyte activation often used as one of
the diagnostic criteria for hemophagocytic syndromes
[13]. This could explain the constellation findings of
SIRS with high a CRP, hypotension, and fever seen in
our series. Similarly, in another report of two patients
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with TT after ICB, one patient had a similar presentation
of rash with SIRS within 8 days of starting V/C after ICB
[14]. Although findings attributed to potential macro-
phage activation syndrome with D/T after ICB have been
reported in the literature [15], no accompanying cutane-
ous features were observed. Thus a deeper understand-
ing of the role of altered cytokine physiology during
these adverse events may facilitate in better management
strategies.
Given that none of our patients had clinical or histo-
logical features concerning for Stevens - Johnson syn-
drome (SJS) and a majority were noted to have disease
progression, an attempt to restart TT (patients 1–4 and
patient-6) was made within 1–8 weeks after the rash. We
observed that delayed re-exposure to the treatment after
completing a steroid taper resulted in rash reoccurrence
whereas re-exposure with steroid overlap was not associ-
ated with rash reoccurrence in our case series. This
again is suggestive of a persisting immune activation
despite drug discontinuation, a feature commonly attrib-
uted to the prolonged pharmacodynamic activity of ICB
which perhaps can be ameliorated using steroids when
opting to re-challenge these patients with TT. Also, of
the five patients who were restarted on TT, four were
able to stay on it with good effect for > 200 days after
re-initiation. Thus the possibility of achieving clinically
meaningful benefit on re-challenging these patients with
TT needs strong consideration (Table 3).
Due to the clinical presentation and the pattern of the
diffuse morbilliform rash, Drug Reaction with Eosino-
philia and Systemic Symptoms (DRESS) syndrome was
considered a leading differential in four of our six
patients. Our patients lacked the severe transaminitis,
eosinophilia, and extended latency periods commonly
seen in DRESS syndrome, but did have features that
would support a diagnosis of “possible” or “probable”
cases by RegiSCAR criteria [16], including fevers, facial
swelling, and duration of the rash. Interestingly, this
atypical pattern of DRESS syndrome, lack of eosinophilia
and shorter latency periods for grade-4 rash, has been
described in other series of patients receiving TT follow-
ing ICB [8]. Nevertheless, a high index of suspicion for
SJS or toxic epidermal necrolysis (TEN) should be main-
tained in all patients presenting with rapid-onset, diffuse
rashes after changes in drug therapy. Although two of
our patients had mucositis, this was limited to the oral
mucosa, and the remainder of the rash did not blister or
desquamate which again did not support SJS. In cases
such as these, a skin biopsy can be particularly helpful in
predicting the clinical course.
Despite the extensive nature of the rash on clinical exam,
the pathologic findings in the skin biopsies for our cases
were relatively mild and primarily characterized by papil-
lary dermal edema with a lympho-eosinophilic infiltrate
(Fig. 3). This pattern of inflammation suggests a delayed
hypersensitivity type reaction. None of the biopsies showed
toxic epithelial changes or interface alterations suggestive
of SJS/TEN, erythema multiforme-like drug reactions or
vasculitis. In contrast, In contrast, the biopsy from
patient-2 displayed distinctive features of sub-epidermal
vesicle formation and positive immunofluorescence studies
supportive of an immunobullous disease. Given that pa-
tient 2 was on TT for a long duration without any CAEs,
we believe that the use of an antibiotic in patient-2 for pos-
sible pneumonia (Table 1) may have worked in conjunction
with the TT (D/T) to produce the dramatic clinical picture
along with the cutaneous findings. In general, the scarcity
of the inflammatory cells and lack of toxic or necrotizing
changes in the cutaneous vessels and epithelium were unit-
ing histopatholic features in our skin specimens.
An important point to note is the timeline of onset
and severity of the CAEs. The median time to onset of
rash in our series was 14.5 days. Development of a rash
within 5–14 days is typical for a morbilliform or simple
drug eruption; in contrast, patients with a systemic drug
hypersensitivity eruption often have a more delayed
presentation 3–6 weeks after drug initiation. Our pa-
tients had features of systemic hypersensitivity but pre-
sented earlier than might be expected for typical
drug-induced hypersensitivity or DRESS syndrome. This
seems distinct from the rash that patients have TT with-
out history of prior immunotherapy in which the dur-
ation of medication exposure prior to rash onset is
longer with less severe systemic symptoms. This could
support the hypothesis that exposure to prior immuno-
therapy led to durable immune alterations which would
then augment a hypersensitivity drug reaction caused by
TT, thus explaining the more rapid onset and the sever-
ity of symptoms, a mechanism proposed by others too
[14]. For now more pre-clinical data to identify molecu-
lar mechanisms linking ICB to TT that could drive these
CAEs is required to support these claims.
Several trials currently underway are aimed at eluci-
dating the utility of using a two-pronged approach of
combining TT and ICB as well as sequencing these
agents [4, 17, 18]. A highly anticipated trial looking into
Table 3 Practical Advice for Clinical Management
- Consult dermatology and biopsy right away, photographs recommended
to help document rash.
- Consider obtaining CRP as surrogate for IL-6 as patients may present
with SIRS.
- Consider re-initiation of therapy after rash (at lower dose, with steroid
overlap), particularly if no signs of SJS, biopsy appears benign relative
to clinical rash, and patient was having a good response to the therapy
or does not have alternate therapy options.
- Consider avoidance of other stimulating medications or known
activating medications such as amoxicillin, amoxicillin-clavulanic acid,
allopurinol
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the optimal sequencing of TT and ICB is the ECOG
phase III study [19] estimated to have results reported by
2022. It is hopeful that the results of these trials will pro-
vide definitive information on the optimal strategy for
sequencing of TT and ICB and thus could have signifi-
cant implications on influencing treatment decisions in
advanced B-RAF mutated melanoma in the near future.
In conclusion, our cases highlight the importance of
maintaining a high index of suspicion for toxicities es-
pecially involving the skin when opting for strategies
that involve sequencing of TT and ICB more so in the
first two to 3 weeks of the switch. Findings from our
cases show that these adverse clinical presentations
with associated cutaneous findings tend to respond well
to supportive measures and steroids. Also, depending
on the disease status and the grading of the reactions, it
may be reasonable to re-challenge select patients under
strict supervision preferably with a steroid overlap even
after rash resolution; keeping in mind that persisting
immune activation from ICB may portend a high risk
of rash reactivation despite several weeks of steroid use.
Given the lack of prospective studies so far, most of our
experiences with such agents administered either se-
quentially or in combination are guided by retrospect-
ive data similar to ours. Hence unraveling principles
governing optimal sequencing or mechanisms contrib-
uting to potential toxicity patterns in patients receiving
these treatments requires further understanding with
prospective evidence.
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